Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
457 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,480 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial(PRISMA) | active not recruiting | Phase 4 | 5,000 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07281547 | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain | not yet recruiting | Phase 4 | 20 | Mayo ClinicOTHER | 1 | Aug 5, 2026 |
| clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07075250 | Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study(RIFOC003) | not yet recruiting | Phase 4 | 30 | Peking University People's HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer(COMPASS) | terminated | Phase 4 | 89 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer(POLO) | unknown | Phase 4 | 102 | Seoul National University HospitalOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT03105856 | FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program(FASTER) | completed | Phase 4 | 3,000 | Instituto Nacional de Salud Publica, MexicoOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT03349463 | Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | unknown | Phase 4 | 30 | Bital Savir-BaruchOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | terminated | Phase 4 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials